Business
Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman
Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL )...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as ChairmanOakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (\"Cardiol\" or the \"Company\"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that its Board of Directors has appointed Dr. Guillermo Torre-Amione as the new Chairman. Dr. Torre-Amione has been an independent director of Cardiol since August 2018 and is taking over from Dr. Eldon Smith, who is the founding Chairman of Cardiol and is now retiring from the Board. \"I am pleased that Dr. Torre-Amione has agreed to serve as Chairman of our Board. Dr. Torre-Amione's exceptional knowledge of and expertise in both scientific and clinical research in heart failure, including the design and execution of pivotal clinical trials, will provide invaluable leadership and guidance during an exciting period of growth for Cardiol,\" said David Elsley, President & CEO of Cardiol Therapeutics.Mr. Elsley continued, \"On behalf of Cardiol and the Board of Directors, I would like to take this opportunity to thank Dr. Eldon Smith for his invaluable contributions to the Company as Chairman and wish him a healthy and happy well-earned retirement.\"Board certified in cardiovascular disease and Advanced Heart Failure/Transplant Cardiology, Dr. Guillermo Torre-Amione is former chief of the Heart Failure Division and former medical director of Cardiac Transplantation at the Houston Methodist DeBakey Heart & Vascular Center. He is also Professor of Cardiology at The Methodist Hospital Research Institute, Houston, Professor of Medicine at the Weill Cornell Medical College of Cornell University, New York, and President of TecSalud, an academic medical center and medical school of the Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM) in Mexico.Dr. Torre-Amione spearheads the Gene and Judy Campbell Laboratory for Cardiac Transplant Research, where his primary areas of research include heart failure, cardiac transplant, and the role of the immune response in modulating the progression of heart failure. Dr. Torre-Amione initiated a series of clinical studies that led to an FDA-approved Phase II clinical trial of neuro...